Request Demo
Last update 24 May 2025
JSKN016
Last update 24 May 2025
Overview
Basic Info
Drug Type Antibody drug conjugate (ADC) |
Synonyms JSKN016 |
Target |
Action modulators, inhibitors |
Mechanism HER3 modulators(Receptor tyrosine-protein kinase erbB-3 modulators), Trop-2 inhibitors(Tumor-associated calcium signal transducer 2 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Boost your research with our ADC technology data.
login
or
Related
7
Clinical Trials associated with JSKN016NCT06942234
The Multicenter, Open-label, Single-arm, Multi-cohort Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of JSKN016 in Combination Therapy in Chinese Participants With Inoperable Locally Advanced or Metastatic HER2-negative Breast Cancer
NCT06868732
Evaluation of JSKN016 Combination Therapy in Subjects with Advanced Non-Small Cell Lung Cancer: a Phase Ib Study
NCT06775483
Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study
100 Clinical Results associated with JSKN016
Login to view more data
100 Translational Medicine associated with JSKN016
Login to view more data
100 Patents (Medical) associated with JSKN016
Login to view more data
100 Deals associated with JSKN016
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Metastatic HER2-Negative Breast Carcinoma | Phase 2 | - | 01 Jun 2025 | |
| HER2-negative breast cancer | Phase 2 | China | 28 Apr 2025 | |
| Adenocarcinoma of Esophagus | Phase 2 | China | 25 Apr 2025 | |
| Advanced Gastroesophageal Junction Adenocarcinoma | Phase 2 | China | 25 Apr 2025 | |
| stomach adenocarcinoma | Phase 2 | China | 25 Apr 2025 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 2 | China | 20 Dec 2024 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 30 Apr 2024 | |
| Advanced breast cancer | IND Approval | China | 20 Mar 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free